Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
276estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-31 | estimated | When the study began enrolling |
| Primary completion | 2025-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Primary outcomes
what the primary-completion date above is the date OFDescription of the lupus-affected population
measured 60 months
Determining the burden of SLE in Egypt
measured 60 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed